Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.

International journal of STD & AIDS - 1 Nov 2010

Clumeck N, Cahn P, Molina J-M, Mills A, Nijs S, Vingerhoets J, Witek J

Abstract excerpt

The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regimen in patients harbouring virus fully sensitive to etravirine. Full etravirine sensitivity was defined as fold change in 50% effective concentration (FC) ≤3 or weighted genotypic score ≤2. At Week 48 in the etravirine group, 74% of patients with etravirine FC ≤3 and 77% with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Darunavir
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Sulfonamides

Share to Viral Load

Source

Identifiers

PMID: 21187353
DOI: 10.1258/ijsa.2010.010139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.PMID 21187353Read ↗

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.Semantic proximity Read ↗

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.Semantic proximity Read ↗

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.Semantic proximity Read ↗

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.Semantic proximity Read ↗

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.Semantic proximity Read ↗

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.Semantic proximity Read ↗

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.Semantic proximity Read ↗

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.